1. Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer
   Vanita Noronha et al, 2017, Cancer Letters CrossRef
2. Targeted therapy and drug resistance in gastric and pancreatic cancer
   Xuan-Dung Ho et al, 2023, Treatment Landscape of Targeted Therapies in Oncology CrossRef
3. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
   Toshiki Iwai et al, 2016, Oncology Reports CrossRef
4. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma
   Zeng Wang-Yuan et al, 2016, International Journal of Hyperthermia CrossRef
5. Tumor endothelial cells as a potential target of metronomic chemotherapy
   Ji Yoon Kim et al, 2019, Archives of Pharmacal Research CrossRef
6. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
   Ching-Wen Huang et al, 2021, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
7. Vascular Endothelial Growth Factor and Cluster of Differentiation 34 for Assessment of Perioperative Bleeding Risk in Gastric Cancer Patients
   Mu-Qing He et al, 2016, Chinese Medical Journal CrossRef
8. The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine
   Wei-Ping Lee et al, 2017, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
9. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles
   Gijung Kwak et al, 2017, Journal of Controlled Release CrossRef
10. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer
    Silvia Camera et al, 2020, Clinical Colorectal Cancer CrossRef
11. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis
    Rei Ogawa, 2017, International Journal of Molecular Sciences CrossRef
12. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
    Gianfranco Natale et al, 2018, Cancer Letters CrossRef
13. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer
    Roberto Filippi et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
14. KELOIDS TREATMENT USING TRIPLE MEDICINE COMBINATION
    V.V. Teplyi et al, 2018, Journal "Medical Science of Ukraine" (NMU) CrossRef
15. Tumor Dormancy, Angiogenesis and Metronomic Chemotherapy
    Gianfranco Natale et al, 2017, Tumor Dormancy and Recurrence CrossRef
16. Treatment Strategies of Gastric Cancer—Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review
    Magdalena Tyczyńska et al, 2021, Journal of Gastrointestinal Cancer CrossRef
17. Metronomic chemotherapy remodel cancer‑associated fibroblasts to decrease chemoresistance of gastric cancer in nude mice
    Chao Wang et al, 2017, Oncology Letters CrossRef
18. Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
    null Maharjan et al, 2019, Pharmaceutics CrossRef
19. Early changes in intravoxel incoherent motion MRI parameters can potentially predict response to chemoradiotherapy in rectal cancer: An animal study
    Liheng Liu et al, 2021, Magnetic Resonance Imaging CrossRef
20. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
    Yoshiaki Nakamura et al, 2021, Nature Reviews Clinical Oncology CrossRef
21. KELOIDS TREATMENT USING TRIPLE MEDICINE COMBINATION
    V.V. Teplyi et al, 2018, Medical Science of Ukraine (MSU) CrossRef
22. Metronomic Chemotherapy for Metastatic Breast Cancer
    Slavomir Krajnak et al, 2022, Oncology Research and Treatment CrossRef